within Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BA02_LevodopaAndDecarboxylaseInhibitor;

model LevodopaAndDecarboxylaseInhibitor
  extends Pharmacolibrary.Drugs.ATC.N.N04BA02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N04BA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Levodopa and decarboxylase inhibitor is a combination drug used in the management of Parkinson's disease. Levodopa is a precursor of dopamine, which is deficient in patients with Parkinson's disease, and the decarboxylase inhibitor (usually carbidopa or benserazide) prevents the peripheral breakdown of levodopa, increasing its availability to the brain. This therapy is widely used and approved in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with Parkinson's disease receiving oral levodopa/benserazide (100 mg/25 mg) with blood sampling in a fasted state.</p><h4>References</h4><ol><li><p>Tambasco, N, et al., &amp; Calabresi, P (2018). Levodopa in Parkinson&#x27;s Disease: Current Status and Future Developments. <i>Current neuropharmacology</i> 16(8) 1239–1252. DOI:<a href=&quot;https://doi.org/10.2174/1570159X15666170510143821&quot;>10.2174/1570159X15666170510143821</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28494719/&quot;>https://pubmed.ncbi.nlm.nih.gov/28494719</a></p></li><li><p>Müller, T (2020). Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson&#x27;s disease. <i>Expert opinion on drug metabolism &amp; toxicology</i> 16(5) 403–414. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2020.1750596&quot;>10.1080/17425255.2020.1750596</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32238065/&quot;>https://pubmed.ncbi.nlm.nih.gov/32238065</a></p></li><li><p>Tuunainen, J, et al., &amp; Yliperttula, M (2023). Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects. <i>European journal of drug metabolism and pharmacokinetics</i> 48(1) 23–34. DOI:<a href=&quot;https://doi.org/10.1007/s13318-022-00800-w&quot;>10.1007/s13318-022-00800-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36309950/&quot;>https://pubmed.ncbi.nlm.nih.gov/36309950</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end LevodopaAndDecarboxylaseInhibitor;
